guest ::
| Home > Publications database > GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients. |
| Home > Publications database > GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients. |
| Journal Article | DKFZ-2025-01806 |
; ; ; ; ; ; ;
2025
BioMed Central
London
This record in other databases: 
Please use a persistent id in citations: doi:10.1186/s12967-025-06993-3
Abstract: Circulating tumour DNA (ctDNA) in liquid biopsies has emerged as a powerful biomarker in cancer patients. Its relative abundance in cell-free DNA serves as a proxy for the overall tumour burden. Here we present GeneBits, a method for cancer therapy monitoring and relapse detection. GeneBits employs tumour-informed enrichment panels targeting 20-100 somatic single-nucleotide variants (SNVs) in plasma-derived DNA, combined with ultra-deep sequencing and unique molecular barcoding. In conjunction with the newly developed computational method umiVar, GeneBits enables accurate detection of molecular residual disease and early relapse identification.To assess the performance of GeneBits and umiVar, we conducted benchmarking experiments using three different commercial cell-free DNA reference standards. These standards were tested with targeted next-generation sequencing (NGS) workflows from both IDT and Twist, allowing us to evaluate the consistency and accuracy of our approach across different oligo-enrichment strategies. GeneBits achieved comparable depth of coverage across all target sites, demonstrating robust performance independent of the enrichment kit used. For duplex reads with ≥ 4x UMI-family size, umiVar achieved exceptionally low error rates, ranging from 7.4×10-7 to 7.5×10-5. Even when including mixed consensus reads (duplex & simplex), error rates remained low, between 6.1×10-6 and 9×10-5. Furthermore, umiVar enabled variant detection at a limit of detection as low as 0.0017%, with no false positive calls in mutation-free reference samples. In a reanalysed melanoma cohort, variant allele frequency kinetics closely mirrored imaging results, confirming the clinical relevance of our method.GeneBits and umiVar enable highly accurate therapy and relapse monitoring in plasma as well as identification of molecular residual disease within four weeks of tumour surgery or biopsy. By leveraging small, tumour-informed sequencing panels, GeneBits provides a targeted, cost-effective, and scalable approach for ctDNA-based cancer monitoring. The benchmarking experiments using multiple commercial cell-free DNA reference standards confirmed the high sensitivity and specificity of GeneBits and umiVar, making them valuable tools for precision oncology. UmiVar is available at https://github.com/imgag/umiVar .
Keyword(s): Humans (MeSH) ; Circulating Tumor DNA: genetics (MeSH) ; Circulating Tumor DNA: blood (MeSH) ; Neoplasms: genetics (MeSH) ; Neoplasms: therapy (MeSH) ; Neoplasms: blood (MeSH) ; High-Throughput Nucleotide Sequencing (MeSH) ; Neoplasm Recurrence, Local: genetics (MeSH) ; Treatment Outcome (MeSH) ; Recurrence (MeSH) ; Liquid Biopsy (MeSH) ; Polymorphism, Single Nucleotide: genetics (MeSH) ; Cell-free DNA ; Circulating tumour DNA ; Liquid biopsy ; Molecular residual disease ; Next-Generation-Sequencing ; Relapse detection ; Treatment monitoring ; Ultra-deep sequencing ; Unique molecular barcode ; Circulating Tumor DNA
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
